SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Laboratory Corp. of America Holdings – ‘8-K’ for 2/23/21 – ‘EX-99.1’

On:  Tuesday, 2/23/21, at 7:00am ET   ·   For:  2/23/21   ·   Accession #:  920148-21-15   ·   File #:  1-11353

Previous ‘8-K’:  ‘8-K’ on / for 2/11/21   ·   Next:  ‘8-K/A’ on 3/3/21 for 11/2/20   ·   Latest:  ‘8-K’ on 4/11/24 for 4/10/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/23/21  Lab Corp. of America Holdings     8-K:7,9     2/23/21   13:191K

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     14K 
 9: R1          Cover page Cover page                               HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- lh-20210223_htm                     XML     23K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- lh-20210223_cal                 XML      7K 
 5: EX-101.DEF  XBRL Definitions -- lh-20210223_def                  XML      9K 
 6: EX-101.LAB  XBRL Labels -- lh-20210223_lab                       XML     69K 
 7: EX-101.PRE  XBRL Presentations -- lh-20210223_pre                XML     33K 
 3: EX-101.SCH  XBRL Schema -- lh-20210223                           XSD     12K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
13: ZIP         XBRL Zipped Folder -- 0000920148-21-000015-xbrl      Zip     15K 


‘EX-99.1’   —   Miscellaneous Exhibit


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

lc2020logov21a.gif




FOR IMMEDIATE RELEASE

Labcorp Contacts:
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

Media: Chris Allman-Bradshaw – 336-436-8263
Media@Labcorp.com

LABCORP IS SCHEDULED TO SPEAK AT CITI'S 2021 HEALTHCARE SERVICES, MEDTECH, TOOLS, & HCIT VIRTUAL CONFERENCE

BURLINGTON, N.C., Feb. 23, 2021Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, Feb. 25 at 1:30 p.m. ET.

A live webcast of the presentation will be available via the company website at www.Labcorp.com and archived for replay.

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the estimated 2021 guidance and the related assumptions, the impact of various factors on operating and financial results, including the projected impact of the COVID-19 pandemic on the company’s businesses, operating results, cash flows and/or financial condition, statements relating to our responses to and the expected future impacts of the COVID-19 pandemic, on our business more generally as well as on general economic, business, and market conditions, future business strategies, expected savings and synergies (including from the LaunchPad initiative and from acquisitions), and the opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company’s control, including without limitation, the impact of the COVID-19 pandemic and its impact on our business and financial condition and on general economic, business, and market conditions, our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, federal, state, and local government responses to the COVID-19 pandemic, the effect of public opinion on the company’s reputation, adverse results in material litigation matters, the impact of changes in tax laws and regulations, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, adverse weather conditions, the number of revenue days in a financial period, employee relations, personnel costs, and the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.






The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the company’s filings with the SEC including the information in the company’s most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the company’s filings with the SEC including the information in the company’s most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

###


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:2/23/21None on these Dates
 List all Filings 
Top
Filing Submission 0000920148-21-000015   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 20, 5:39:31.2am ET